Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended dose for phase II studies, and to explore its efficacy. We assessed toxicities and explored the activity of the drug combination exclusively in patients with malignant pleural me...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 20; číslo 16; s. 3533
Hlavní autoři:	Hughes, Andy, Calvert, Paula, Azzabi, Ashraf, Plummer, Ruth, Johnson, Rob, Rusthoven, Jim, Griffin, Melanie, Fishwick, Kevin, Boddy, Alan V, Verrill, Mark, Calvert, Hilary
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 15.08.2002
Témata:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Area Under Curve Carboplatin - administration & dosage Dose-Response Relationship, Drug Female Glutamates - administration & dosage Guanine - administration & dosage Guanine - analogs & derivatives Hematologic Diseases - chemically induced Humans Male Maximum Tolerated Dose Mesothelioma - drug therapy Mesothelioma - mortality Middle Aged Pemetrexed Pleural Neoplasms - drug therapy Pleural Neoplasms - mortality Survival Rate
ISSN:	0732-183X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!